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Chronic venous ulcers (VUs) afflict 2% of the
adult population in Western countries and cost
between $775 million and $1 billion per year to
treat.1,2 The understanding of the pathogenesis of
venous ulceration is incomplete, but chronic
venous hypertension is thought to be the key
instigator that leads to chronic venous insufficien-
cy and ulceration.1
Because these lesions result from chronic venous
hypertension, conventional management has focused
on attempts at improving venous hemodynamics with
local compression, superficial venous stripping, and
subfascial endoscopic perforator surgery (SEPS).3-7
These techniques address the hemodynamic distur-
bance but ignore the other aspect of venous ulcera-
tion, the surrounding lipodermatosclerosis (LDS),
which is a chronically scarred, poorly vascularized,
fragile tissue bed that is likely to ulcerate and is diffi-
cult to heal.8 This may explain why some ulcers will
not heal despite optimal treatment and why as many
as 60% recur after initial healing.3-7
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Background: Most venous ulcers (VUs) will heal with conventional treatment, which
focuses on improving regional venous hemodynamics. This treatment, however, often
fails to heal large, recurrent VUs that are associated with severe lipodermatosclerosis
(LDS). These complicated ulcers may require correction of local venous hemodynamics
and replacement of the surrounding LDS with healthy tissue. We report our experience
managing 24 especially difficult VUs with debridement and free flap coverage.
Patients and Methods: Between 1987 and 1997, 25 free flap procedures were performed
in 22 patients for 24 recalcitrant VUs. Ulcers had been present for a mean of 5.24 years
and had failed to heal with conservative therapy and split-thickness skin grafts (STSGs)
(mean, 2.2). Eleven patients (46%) had exposed bone, tendon, or joint. At operation the
area of LDS was excised, and all perforating veins were ablated. The defects after exci-
sion ranged from 100 to 600 cm2 (mean, 237 cm2). The free flap was inset within the
defect and covered with an STSG.
Results: We healed all 24 ulcers with free tissue transfer (one patient required a second
flap after the first failed). There were no deaths. Local complications that required
repeat STSG occurred in three (13%) of the 24 successful flap transfers. Four other flaps
had minor local complications that healed with local wound care. Follow-up was avail-
able for 21 of the 24 successful flap transfers. No recurrent ulcers were identified in the
territory of the flap after a mean of 58 months, but three patients had new ulcers in the
same leg after 6 to 77 months. Patients with severe complications were hospitalized
longer than those with minor or no complications (45.7 vs 12.8 days, P <.01), and their
hospital charges were greater ($76,681 vs $30,428, P <.01).
Conclusion: Free tissue transfer can provide rapid healing and long-term relief from severe
VUs that are unable to be treated with conventional therapy. This technique improves
venous hemodynamics, removes all liposclerotic tissue, provides an abundant blood sup-
ply, and resolves the tissue-related components of chronic ulceration. Although further
work is needed to determine the optimal indications, this technique provides a durable
treatment for especially recalcitrant ulcers. (J Vasc Surg 2000;32:848-54.)
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Clearly, correction of venous hypertension with
compression therapy or surgery does provide relief
in some patients. However, a subgroup of ulcers will
not heal with either of these approaches or will con-
tinue to recur. Which group of ulcers will heal has
not yet been elucidated, but we know from the
SEPS experience that large ulcers and ulcers in post-
phlebitic limbs take longer to heal and postphlebitic
ulcers recur more frequently than ulcers arising in
limbs with primary venous insufficiency.7
We propose that the management of large, com-
plicated, recurrent ulcers associated with severe der-
mal scarring requires more than just improvement in
venous hemodynamics. Optimal treatment of these
severe, recalcitrant ulcers includes not only correct-
ing venous hemodynamics but also addressing the
surrounding irreversibly scarred areas of LDS.9-15
This can be accomplished by the removal of all
liposclerotic tissue followed by free tissue transfer to
close the resulting large soft tissue defect. We report
our experience in managing a group of difficult VUs
that were refractory to other forms of therapy. In
addition, we analyzed hospital lengths of stay and
the charges associated with free tissue transfer.
PATIENTS AND METHODS
Patients. Over the last 12 years we performed 25
free tissue transfers (23 muscle and 2 omentum) in 22
patients for the treatment of 24 nontraumatic, nonos-
teomyelitic VUs at three institutions. Patient demo-
graphics are shown in Table I. Sixteen male and seven
female patients were aged from 17 to 76 years (mean,
44 years). Five patients had a history of deep venous
thrombosis (23%). Four patients had a history of
peripheral vascular disease that had required interven-
tion in the past (3 bypass grafts and 1 angioplasty).
None of these procedures had been performed in
preparation of or in conjunction with a flap procedure.
These patients had ulcers that were especially
severe and represent a small fraction of the patients
with ulcers we see overall. They were culled from a
multidisciplinary clinic where now approximately 20
patients are seen each week, including one or two new
patients. Several of the patients in this series were
overweight, but none were morbidly obese. One
patient had rheumatoid arthritis, but no other patient
had any associated systemic illnesses that may have
contributed to ulcer development or persistence.
The ulcers had been present for a mean of 5.24
years (median, 4.9 years; range, 1-22 years). All
failed to be healed with the best medical therapy,
including compression with a 30– to 40–mm Hg
hose. All patients had received this treatment for at
least 1 year and most for considerably longer. A
mean of 2.2 split-thickness skin grafts (STSGs)
(range, 0-6 grafts) had been applied and failed. All
ulcers were distal to the midcalf and were located
medially in 11 patients, laterally in 6, anteriorly in 5,
and circumferentially in 3. Eleven (46%) had
exposed bone, tendon, or joint. The defects that
resulted from excision of the ulcer and surrounding
lipodermatosclerotic skin ranged from 100 to 600
cm2 (mean, 237 cm2).
Preoperative evaluation. The patients were
evaluated by both vascular and plastic surgery ser-
vices. A detailed history was taken, and a physical
examination and noninvasive arterial and venous
studies were performed. Our preoperative venous
evaluation has evolved over time. The first nine
patients were treated at an institution without a vas-
cular laboratory. Consequently, these patients were
studied only by means of a noninvasive arterial
examination. Later, we used duplex scan and photo-
plethysmography (PPG). Of the newest 13 patients
at the University of Illinois, 12 underwent preoper-
ative noninvasive venous testing, 11 with PPG and 9
with duplex scan. Duplex scan was used to examine
for signs of previous deep venous thrombosis and
obstruction. It was not used to evaluate for reflux.
None of the patients studied had obstruction of
their deep system. Of the 11 patients who under-
went preoperative PPG testing, 8 had deep reflux, 2
had superficial reflux only, and 1 had normal refill-
ing times. These latest patients also underwent
Table II. Hospital charges
Service All patients
Operating room $18,369 





Table I. Patients and ulcers
Mean age 44 y
Male 73%
History of DVT 5/22 (23%)
Mean defect size 237 cm2
Mean ulcer duration 5.2 y
Exposed bone/tendon/joint 11/24 (46%)
Mean failed STSG 2.2
DVT, Deep venous thrombosis; STSG, split-thickness skin graft.
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duplex scan interrogation to identify, localize, and
mark all perforating veins preoperatively.
Noninvasive Doppler scan–derived waveform
analysis and duplex scan visualization of the intend-
ed target vessel were used to evaluate arterial inflow.
Angiography was reserved for vessels with suspected
compromise, as determined with the noninvasive
testing, and was performed in four patients to help
select appropriate arterial inflow for the flap. 
Before operation, the ulcers were treated with
debridement, local wound care, and antibiotics as
necessary to control infection. When the ulcers were
clean without clinical signs of infection, they were
considered ready for the free flap. Approximately 5
days before the procedure, biopsies of the ulcers
were performed for a quantitative culture that
helped guide perioperative antibiotic coverage.
Appropriate antibiotics were administered 1 hour
before the procedure and for 5 days after.
Postoperatively, all patients received sodium heparin
(5000 units) subcutaneously twice a day and aspirin.
Operative technique. All procedures were per-
formed in a single stage, and no patient underwent
adjunctive procedures before or during the flap pro-
cedure. Two teams performed the operations using
separate instruments with divided surgical fields to
avoid contamination of the flap donor site. The plas-
tic surgeons began by harvesting the free flap. The
latissimus dorsi muscle was used to cover large
defects, the rectus abdominis or split latissimus dorsi
muscle for moderately sized wounds, and the serra-
tus or gracilis muscle for smaller ulcers. In one case
an omental free flap was used in a patient who
required coverage of bilateral ulcers.
Concurrent with the flap harvest, the vascular
surgery team prepared the leg. The area of hyperpig-
mentation and LDS, which was defined with inspec-
tion and palpation, was excised to the healthy tissue
to both deep and circumferential margins. This
required the removal of the fascia with the specimen.
Care was taken to ablate all preoperatively identified
perforating veins. The recipient bed was meticulous-
ly debrided and then copiously irrigated with a pulse-
jet irrigator with saline-containing bacitracin.
The arterial inflow to the flap was chosen because
of the location of the lesion and the hemodynamic or
arteriographic status of the artery. Only those arteries
that were hemodynamically normal as assessed with
noninvasive arterial studies were used. The recipient
artery and vein were identified and dissected. The
posterior tibial artery was usually the preferred vessel
because most ulcers were located medially and in our
experience, this artery has the lowest potential for
spasm. If the posterior tibial artery was hemodynami-
cally abnormal or if the ulcer was located anteriorly,
the anterior tibial artery was used for inflow. The per-
oneal artery was used only if both tibial arteries were
diseased. Venous outflow went to the corresponding
venae comitantes, except in one case where a cephal-
ic vein segment containing competent valves was
interposed between the flap and popliteal vein.
When the flap was ready for harvest, the patient
was anticoagulated intravenously with 100 U/kg of
sodium heparin. The free flap was disconnected
from its blood supply and anastamosed to the donor
artery in end-to-side fashion and to the vein in end-
to-end fashion. All anastomoses were performed
with interrupted 8-0 or 9-0 nylon suture by the use
of the operating microscope. The flaps were inset
within the defect and then covered with an STSG
that was harvested from the opposite lower extrem-
ity and meshed 1.5:1.
Postoperative care. Patients recovered in an
intensive care unit where the flap was monitored
hourly. The patients continued to receive oral aspirin
daily and minidose heparin (5000 units twice a day),
but systemic anticoagulation was not routinely used.
After complete healing of the skin grafts, the patients
were fitted with 20– to 30–mm Hg support hose
and instructed to avoid prolonged standing. Oral
aspirin was continued for 6 weeks. None of the flaps
required debulking because of muscle atrophy.
Data analysis. We examined the charges associ-
ated with this procedure and its hospitalization to
Table III. Comparison of hospital charges
Service Severe complication Minor or no complications P value
Operating room $28,020 ± $2419 $15,464 ± $1631 .003
Room and board $33,200 ± $4560 $9433 ± $1102 .037
Pharmacy $10,561 ± $2173 $3176 ± $514 .084
Laboratory $4587 ± $356 $2106 ± $443 .019
Radiology $313 ± $113 $248 ± $66 .817
Total $76,681 ± $6645 $30,428 ± $3179 .0001
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evaluate the expense for this approach. The charts of
the newest 13 patients treated at the University of
Illinois Hospital were examined, and all charges that
were billed were recorded. We separated the charges
into five areas: room and board, operating room,
pharmacy, radiology, and laboratory. Surgical profes-
sional fees were not included in this assessment.
Statistical analysis. Length of stay and cost data
were analyzed with a computerized statistical soft-
ware program (Instat, 3.0 for Windows; Graph Pad
Software, Inc, San Diego, Calif). A 2-tailed unpaired
t test was used for normally distributed data. If SDs
were significantly different, a Welch correction was
performed. Data were analyzed to ensure that they
were distributed normally with the method of
Kolmogorov and Smirnov. Abnormally distributed
data were analyzed with the Mann-Whitney test.
RESULTS
Operative results. Between 1987 and 1997, 23
muscle and two omental free flap procedures were
performed in 22 patients for 24 recalcitrant VUs.
Three patients underwent two flap procedures. One
patient had bilateral ulcers treated simultaneously
with hemiomental free flaps. Another patient had a
separate ulcer 2 years after the first and received a
second flap. A third patient, whose first flap failed,
received a second flap for the same ulcer. All soft tis-
sue specimens had been sent for pathologic exami-
nation. None showed any malignant change.
The defects were most commonly covered with a
rectus abdominis muscle free flap (n = 16) followed
by the latissimus dorsi muscle (n = 5), the omentum
(n = 2), and the gracilis (n = 1) or serratus muscle (n
= 1). The posterior tibial artery was the most com-
mon inflow vessel (n = 15). The anterior tibial artery
was used in eight cases and the peroneal in two. Flap
ischemia time averaged 1.77 hours (range, 0.75-3.0
hours). Total operative time averaged 7.32 hours
(range, 3.5-11 hours) for the unilateral cases, and 10
hours were required for the one bilateral case.
Free tissue transfer was successful in 24 (96%) of
25 flaps. One flap failed because of intractable
vasospasm. This patient had a history of recent
cocaine abuse. Several months later, another flap
procedure was successful when performed after the
patient stopped using cocaine.
Complications. There were no deaths. Com-
plications occurred in eight (33%) of the 24 success-
ful flap transfers. Seven of these complications were
in patients who lost areas of flap or skin graft. Four
patients were healed with local wound care, but the
other three required additional procedures. One flap
failed partially because of intractable vasospasm. This
occurred in a patient who was undergoing long-
term treatment with prednisone for control of
rheumatoid arthritis. Although 50% of her flap
necrosed, sufficient tissue survived to allow another
skin graft. This ulcer remains healed without recur-
rence after 27 months. Two other patients lost
smaller areas of flap and required repeat skin grafts.
The other complication was a minor abdominal
wound dehiscence following a rectus muscle free
flap that caused a small incisional hernia.
Follow-up. Long-term follow-up was available
for 19 patients with 21 of the 24 successful flap
transfers. No ulcers were identified in any flap after a
mean of 58 months (range, 25-97 months).
However, three patients did have a separate ulcer in
the same leg after the free flap procedure at 6, 24,
and 77 months. All of these ulcers occurred laterally
or posterolaterally, and all patients had undergone
debridement and coverage of large medial ulcers.
One patient received a second flap and did well. The
other two have not been healed with conservative
therapy, and these patients are being evaluated for
another flap procedure.
Cost and length of stay. The patients were hos-
pitalized for an average of 20 days after the proce-
dure (range, 7-55 days). The three patients who had
complications that required a repeat operation for
debridement and skin grafting remained in the hos-
Table IV. Free flaps for VUs
Author Type of flap n Success Flap recurrence New ulcer Follow-up (y)
Allen (1989) Muscle 2 100% 0 2-5
Swartz (1989) Muscle 7 100% 0 4 (mean)
Ramirez (1992) Muscle 13 77% 0 1-7
Steffe (1998) Muscle 14 86% 0 100% 5.4 (mean)
Dunn (2000) Fasciocutaneous 23 100% 0 18% 4 (mean)
Kumins (2000) Muscle/omentum 25 96% 0 13% 2-8
Total 84 93% 0
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pital for an average of 45.7 days (range, 32-55 days).
This was significantly longer than the patients with
minor or no complications, who averaged 12.8 days
(range, 7-16 days; P < .01).
We examined the charges for this procedure and
its attendant hospitalization to evaluate the expense
associated with this approach. We analyzed the hos-
pital charges for the latest 15 procedures that were
performed in 13 patients at the University of Illinois
Hospital (Tables II and III). Total charges ranged
from $19,856 to $86,505 (mean, $41,457). The
charges for patients with complications who required
repeat operation averaged $76,681 (range, $64,081-
$86,505), whereas charges for patients with minor or
no complications averaged $30,428 (range,
$19,856-$44,615; P < .01). Patients with complica-
tions who required reoperation had higher operating
room costs ($28,020 vs $15,474; P < .01), and their
longer length of stay significantly increased room and
board costs ($33,200 vs $9504; P < .05).
DISCUSSION
This report summarizes our results with free tis-
sue transfer in the management of chronic large VUs
that failed to heal with conventional therapy.
Twenty-four ulcers were successfully treated
through excision of diseased tissue followed by free
flap coverage. All ulcers were healed with this tech-
nique, although one patient required a second flap
after his first one failed. In most cases, these flap pro-
cedures allowed healing to occur within weeks. No
ulcers were noted to recur in the flaps after a mean
follow-up of 58 months. Although wound compli-
cations occurred after 33% of the operations, most
were managed conservatively.
All of the ulcers we treated were severe and
refractory to conventional treatment. These patients
were culled from a multidisciplinary clinic where
complex venous disease is managed. Many patients
were referred because of the refractory nature of
their lesions. These ulcers had been present for an
average of 5.2 years and had failed to heal despite
optimal wound care and an average of 2.2 skin grafts
per ulcer. Three ulcers were circumferential, and
46% had exposed bone, tendon, or joint. The ulcers
were large, and the defects after excision of diseased
tissue ranged from 100 to 600 cm2 (average, 237
cm2). These facts define the severity, complexity, and
refractory nature of the lesions treated.
We think that patients with severe VUs require
an approach that addresses both the venous hyper-
tension and the area of ulcerative LDS. Current
treatment strategies correctly focus on improving
regional venous hemodynamics but do not address
the severely diseased liposclerotic tissue.3-7 The rad-
ical approach described in this article has succeeded
where lesser attempts failed for several reasons. First,
both the ulcer and the irreversibly scarred, poorly
vascularized tissue bed were removed, thus prevent-
ing future ulceration. Second, the area was covered
with healthy, well-vascularized tissue, which
increased blood supply to the area. Third, all perfo-
rating veins were ablated during ulcer excision. Each
perforator was marked preoperatively and carefully
ligated during surgery. Finally, the muscle free flap
contains numerous functioning microvenous valves
that act to restore normal regional venous hemody-
namics. The presence and functionality of these
valves in major muscle groups and free flap tissue
pedicles have been extensively described.9-15
Five other groups reported that the use of free
tissue transfer in the treatment of difficult VUs
resulted in reliable coverage (Table IV). Allen et al16
were the first to describe the use of muscle free flaps
in the successful treatment of two VUs that had
been present for more than 10 years. Similarly,
Swartz reported 7, Ramirez 12, and Steffe and
Caffee 14 intractable VUs that were successfully
managed with debridement and muscle free flap
coverage.17-19 Dunn et al10,11 used a fasciocuta-
neous free flap instead of muscle that was successful
in treating 23 VUs. No ulcer recurrences in the ter-
ritory of the flap were identified in these reports
with follow-up as long as 8 years. Eighty-four free
Table V. VU classification
Clinical class Recurrence Size Associated LDS
I No < 2 cm single Mild
II No > 2 cm single or multiple Mild to moderate
III Yes < 20 cm2 total area Moderate to severe
IV Yes > 20 cm2 total area Severe
V Yes Circumferential, exposed bone, tendon, joint Beyond LDS, irreversible scarring
LDS, Lipodermatosclerosis; VU, venous ulcer.
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flaps, including patients from this series, have been
reported in the treatment of chronic VUs with an
overall success rate of 93%.
Although these flaps are durable and no ulcers
have been noted within the territory of the trans-
planted flap, the remainder of the leg remains vulner-
able. Future de novo ulceration elsewhere on the leg
has been reported.9,10,19,20 Three patients in our
series had a separate ulcer in the same leg after the free
flap procedure at 6, 24, and 77 months. All of these
ulcers occurred laterally or posterolaterally in limbs
that had received debridement and coverage of large
medial ulcers. Other authors have reported the devel-
opment of new ulcers in previously intact skin at flap
margins. Dunn et al10 noted this type of ulceration in
18% of 23 fasciocutaneous flaps after a mean of 49
months, and Steffe and Caffee19 noted this in all 12
of their patients after a mean of 17 months. Although
we were initially cautious for fear of debriding too
much tissue and leaving a large defect if the flap failed,
leaving diseased tissue behind is more problematic.
We have become even more aggressive and think that
any tissue that is hyperpigmented, indurated, scarred,
or ulcerated should be removed to avoid marginal
recurrence. None of the three patients who had cir-
cumferential debridement and coverage had any
problems with new ulcer formation.
As part of this study we examined the charges
associated with this procedure and compared the
patients who had complications requiring reopera-
tion with the patients who had relatively minor or no
complications. The total charges for patients with-
out major complications averaged $30,428.
Approximately half of this was incurred in the oper-
ating room, and the bulk of the remainder was for
room and board. With increased experience we may
be able to decrease these charges.
On the surface, this procedure seems costly, but
conservative treatment of chronic VUs is not inex-
pensive. According to a 1993 study in Riverside,
England, the annual cost of treating patients with
long-term VUs was £1334 per year, or roughly
$2267.21 In the Lothian and Forth Valley trial the
total direct and indirect costs of treating 200
patients over a 6-month period was £193,000, or
$3185 per patient per year.22 In patients who
required a visiting nurse, the monthly cost was esti-
mated to be $1928, or $23,000 per year in a 1991
Boston study.23 These reports show that years of
conservative therapy can be as expensive or more
expensive than this operative approach.
Free flaps have been used to treat soft tissue
defects in the lower extremity that result from other
diseases including sickle cell disease, osteomyelitis,
arterial insufficiency, diabetes, and trauma.24-29 The
concept that chronic VUs are incurable and there-
fore not worthy of the radical nature and expense of
free flap techniques needs to be dispelled. We think
that it is inappropriate to condemn patients to life-
long recurrent ulceration and to force on them
extended periods of convalescence to heal large
ulcers. Although we have not shown that the large
up-front costs associated with this procedure are less
than long-term care, in the long run, we think that
it is unethical to deny patients this procedure on the
basis of cost considerations alone.
Clearly, not all ulcers deserve such a radical
approach. Compression therapy, superficial venous
stripping, and SEPS are effective in managing some
ulcers, but they are ineffective in a subgroup of
patients. One problem in evaluating the optimal
indications for various treatment options is that
there is no widely accepted classification scheme that
stratifies active ulcers according to severity or com-
plexity. Current reporting standards (CEAP) pro-
vide good information concerning chronic venous
insufficiency in general but do not separate ulcers
into grades on the basis of severity.30 In the CEAP
classification all active ulcers are placed into clinical
class 6, but this does not take into account ulcer size,
recurrence, multiple ulceration, associated LDS, or
exposed bone, tendon, or joint. We used a simple
classification scheme that discriminates among ulcers
with these criteria to help select our patients and to
clarify some of these issues (Table V).
We think that small, uncomplicated ulcers (class-
es I and II) should be treated with standard thera-
pies such as compression, superficial venous strip-
ping, or SEPS. We think that patients with large,
recurrent VUs associated with severe LDS or injury
that goes “beyond lipodermatosclerosis” into irre-
versible dermal scarring and chronic dermatitis
(classes IV and V) are more appropriately managed
with free flap procedures. We have used this
approach only for ulcers that were refractory to
other forms of therapy.
The development of SEPS has sparked a new
interest in the surgical treatment of VUs. SEPS has
been noted to hasten the healing of VUs, but it has
several shortcomings. First, not all ulcers heal rapidly
with SEPS. According to the North American SEPS
Registry,7 at 6 months only 71% of ulcers larger than
2 cm were healed compared with 93% that were
healed in ulcers less than 2 cm. All ulcers in our series
were much larger. Also, ulcers in post-thrombotic
limbs do worse. These ulcers required 50% more
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time to heal (64 vs 43 days), and twice as many
recurred. Cumulative 2-year recurrence was 46% in
post-thrombotic limbs compared with 20% in
patients with primary valvular insufficiency.
CONCLUSION
Wide local debridement and free tissue transfer
are alternatives or adjuncts to conventional superfi-
cial venous stripping and SEPS. They are particular-
ly applicable to huge ulcers, circumferential ulcers,
and those that are associated with exposed bone,
tendon, or joint. The techniques, with which hun-
dreds of functioning microvenous valves are trans-
planted, are substitutes for valve plasty, and they may
be applied to the post-thrombotic limbs that
respond poorly with SEPS. Although further work is
required to determine the optimal indications for
free flap procedures, we are thus far encouraged by
our results in providing our patients relief from what
was to them an incurable condition.
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